| Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| McKenna Mark C. | Chairman, President & CEO | Mar 15 | Option Exercise | 2.90 | 25,000 | 72,500 | 80,144 | Mar 17 09:02 PM | | McKenna Mark C. | Chairman, President & CEO | Mar 15 | Sale | 116.14 | 25,000 | 2,903,500 | 55,144 | Mar 17 09:02 PM | | Cedars Sinai Intellectual Prop | 10% Owner | Mar 08 | Sale | 114.59 | 865,000 | 99,120,350 | 4,001,132 | Mar 08 09:30 PM | | Marshall Keith W | Chief Financial Officer | Mar 06 | Option Exercise | 3.70 | 10,000 | 37,000 | 19,811 | Mar 08 09:33 PM | | Marshall Keith W | Chief Financial Officer | Mar 06 | Sale | 122.13 | 10,000 | 1,221,300 | 9,811 | Mar 08 09:33 PM | | McKenna Mark C. | Chairman, President & CEO | Mar 03 | Option Exercise | 3.70 | 10,620 | 39,294 | 65,764 | Mar 03 09:30 PM | | McKenna Mark C. | Chairman, President & CEO | Mar 03 | Sale | 125.13 | 10,620 | 1,328,881 | 55,144 | Mar 03 09:30 PM | | McKenna Mark C. | Chairman, President & CEO | Mar 01 | Option Exercise | 3.70 | 700 | 2,590 | 55,844 | Mar 03 09:30 PM | | McKenna Mark C. | Chairman, President & CEO | Mar 01 | Sale | 125.26 | 700 | 87,682 | 55,144 | Mar 03 09:30 PM | | McKenna Mark C. | Chairman, President & CEO | Feb 17 | Option Exercise | 3.70 | 13,680 | 50,616 | 68,824 | Feb 17 09:31 PM | | McKenna Mark C. | Chairman, President & CEO | Feb 17 | Sale | 125.10 | 13,680 | 1,711,368 | 55,144 | Feb 17 09:31 PM | | McKenna Mark C. | Chairman, President & CEO | Feb 16 | Option Exercise | 3.70 | 25,000 | 92,500 | 80,144 | Feb 17 09:31 PM | | McKenna Mark C. | Chairman, President & CEO | Feb 16 | Sale | 119.87 | 25,000 | 2,996,750 | 55,144 | Feb 17 09:31 PM | | McKenna Mark C. | Chairman, President & CEO | Feb 15 | Option Exercise | 2.90 | 25,000 | 72,500 | 80,144 | Feb 17 09:31 PM | | Marshall Keith W | Chief Financial Officer | Feb 15 | Option Exercise | 3.70 | 5,000 | 18,500 | 14,811 | Feb 17 09:34 PM | | McKenna Mark C. | Chairman, President & CEO | Feb 15 | Sale | 119.42 | 25,000 | 2,985,500 | 55,144 | Feb 17 09:31 PM | | Marshall Keith W | Chief Financial Officer | Feb 15 | Sale | 119.38 | 5,000 | 596,900 | 9,811 | Feb 17 09:34 PM | | McKenna Mark C. | Chairman, President & CEO | Jan 17 | Option Exercise | 2.90 | 25,000 | 72,500 | 80,144 | Jan 19 08:39 PM | | Marshall Keith W | Chief Financial Officer | Jan 17 | Option Exercise | 3.70 | 5,000 | 18,500 | 14,811 | Jan 19 08:42 PM | | McKenna Mark C. | Chairman, President & CEO | Jan 17 | Sale | 118.99 | 25,000 | 2,974,750 | 55,144 | Jan 19 08:39 PM | | Marshall Keith W | Chief Financial Officer | Jan 17 | Sale | 119.00 | 5,000 | 595,000 | 9,811 | Jan 19 08:42 PM |
|
